Sobczak A - Search Results

1

A comparison of native and non-urate Total Antioxidant Capacity of fasting plasma and saliva among middle-aged and older subjects.

Gawron-Skarbek A, Prymont-Przymińska A, Sobczak A, Guligowska A, Kostka T, Nowak D, Szatko F. Gawron-Skarbek A, et al. Among authors: sobczak a. Redox Rep. 2018 Dec;23(1):57-62. doi: 10.1080/13510002.2017.1392714. Epub 2017 Oct 31. Redox Rep. 2018. PMID: 29088986 Free PMC article.

2

Analysis of Sartans: a review.

Muszalska I, Sobczak A, Dołhań A, Jelińska A. Muszalska I, et al. Among authors: sobczak a. J Pharm Sci. 2014 Jan;103(1):2-28. doi: 10.1002/jps.23760. Epub 2013 Nov 13. J Pharm Sci. 2014. PMID: 24227012 Review.

3

Stability of epidoxorubicin in solid state.

Sobczak A, Jelińska A, Leśniewska M, Firlej A, Oszczapowicz I. Sobczak A, et al. J Pharm Biomed Anal. 2011 Mar 25;54(4):869-72. doi: 10.1016/j.jpba.2010.10.024. Epub 2010 Nov 2. J Pharm Biomed Anal. 2011. PMID: 21112717

4

Determination of vitamin B6 by means of differential spectrophotometry in pharmaceutical preparations in the presence of magnesium compounds.

Muszalska I, Puchalska M, Sobczak A. Muszalska I, et al. Among authors: sobczak a. Acta Pol Pharm. 2011 Nov-Dec;68(6):845-51. Acta Pol Pharm. 2011. PMID: 22125948 Free article.

5

Determination of adamantane derivatives in pharmaceutical formulations by using spectrophotometric UV-Vis method.

Sobczak A, Muszalska I, Rohowska P, Inerowicz T, Dotka H, Jelińska A. Sobczak A, et al. Drug Dev Ind Pharm. 2013 May;39(5):657-61. doi: 10.3109/03639045.2012.684391. Epub 2012 May 9. Drug Dev Ind Pharm. 2013. PMID: 22568696

6

Hepatitis C - New drugs and treatment prospects.

Zając M, Muszalska I, Sobczak A, Dadej A, Tomczak S, Jelińska A. Zając M, et al. Among authors: sobczak a. Eur J Med Chem. 2019 Mar 1;165:225-249. doi: 10.1016/j.ejmech.2019.01.025. Epub 2019 Jan 14. Eur J Med Chem. 2019. PMID: 30685524 Review.

7

Stability of ceftazidime pentahydrate in medicinal preparations Biotum and Ceftim.

Zajac M, Jelińska A, Sobczak A, Musiał W. Zajac M, et al. Among authors: sobczak a. Acta Pol Pharm. 2005 Jan-Feb;62(1):11-5. Acta Pol Pharm. 2005. PMID: 16022488

8

Mechanism of solvolysis of N-[2-(4-o-fluorophenylpiperazin-1-yl)ethyl]-2,5-dimethyl-1-phenylpyrrole-3,4-dicarboximide (PDI).

Sobczak A, Zajac M, Malinka W, Redzicka A. Sobczak A, et al. Acta Pol Pharm. 2010 May-Jun;67(3):225-32. Acta Pol Pharm. 2010. PMID: 20524423 Free article.

9

The stability of N-[2-(4-o-fluorophenylpiperazin-1-yl)ethyl]-2,5-dimethyl-1 -phenylpyrrole-3,4-dicarboximide in aqueous-organic solutions.

Zajac M, Sobczak A, Malinka W, Redzicka A. Zajac M, et al. Among authors: sobczak a. Acta Pol Pharm. 2010 Jan-Feb;67(1):27-33. Acta Pol Pharm. 2010. PMID: 20210076 Free article.

10

New fluphenazine analogue with antimutagenic and anti-multidrug resistance activity-degradation profile and stability-indicating method.

Sobczak A, Teżyk A, Szyndlarewicz J, Ziarniak J, Świątek P, Malinka W. Sobczak A, et al. Med Chem Res. 2017;26(10):2443-2451. doi: 10.1007/s00044-017-1944-4. Epub 2017 Jun 15. Med Chem Res. 2017. PMID: 29051697 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

201 results

Search Page